PL3504214T3 - Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami - Google Patents
Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusamiInfo
- Publication number
- PL3504214T3 PL3504214T3 PL17771587T PL17771587T PL3504214T3 PL 3504214 T3 PL3504214 T3 PL 3504214T3 PL 17771587 T PL17771587 T PL 17771587T PL 17771587 T PL17771587 T PL 17771587T PL 3504214 T3 PL3504214 T3 PL 3504214T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds useful
- fused tricyclic
- pyridazinone compounds
- treat
- orthomyxovirus infections
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380712P | 2016-08-29 | 2016-08-29 | |
| EP17771587.7A EP3504214B1 (en) | 2016-08-29 | 2017-08-25 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
| PCT/IB2017/055137 WO2018042303A1 (en) | 2016-08-29 | 2017-08-25 | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3504214T3 true PL3504214T3 (pl) | 2021-07-19 |
Family
ID=59923494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17771587T PL3504214T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
| PL20210329.7T PL3848372T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20210329.7T PL3848372T3 (pl) | 2016-08-29 | 2017-08-25 | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10160764B2 (pl) |
| EP (3) | EP3504214B1 (pl) |
| JP (2) | JP7221861B2 (pl) |
| CN (2) | CN113683614A (pl) |
| AR (1) | AR109438A1 (pl) |
| CA (1) | CA3035302A1 (pl) |
| ES (1) | ES2859510T3 (pl) |
| JO (1) | JOP20170169A1 (pl) |
| MX (1) | MX2019002438A (pl) |
| PL (2) | PL3504214T3 (pl) |
| PT (2) | PT3848372T (pl) |
| SI (2) | SI3848372T1 (pl) |
| TW (2) | TW202342482A (pl) |
| UY (1) | UY37378A (pl) |
| WO (1) | WO2018042303A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102468319B1 (ko) * | 2013-09-12 | 2022-11-16 | 얀센 바이오파마, 인코퍼레이트. | 아자-피리돈 화합물 및 이의 용도 |
| MA44080A (fr) | 2015-12-15 | 2018-10-24 | Shionogi & Co | Médicament pour traiter la grippe caractérisé en ce qu'il comprend une combinaison d'un inhibiteur d'endonucléase coiffe-dépendante avec un médicament antigrippal |
| WO2017153919A1 (en) | 2016-03-08 | 2017-09-14 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
| AR109315A1 (es) | 2016-08-10 | 2018-11-21 | Shionogi & Co | Composiciones farmacéuticas que contienen derivados de piridona policíclica sustituida y profármaco de las mismas |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| CN111848614B (zh) | 2018-01-17 | 2021-11-23 | 江西彩石医药科技有限公司 | 吡啶酮衍生物及抗流感病毒药物组合物 |
| SG11202007718SA (en) * | 2018-02-28 | 2020-09-29 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
| CN108440564B (zh) * | 2018-04-11 | 2019-08-06 | 安帝康（无锡）生物科技有限公司 | 被取代的多环氨基甲酰基吡啶酮衍生物及其前药 |
| AU2019359539A1 (en) | 2018-10-10 | 2021-04-29 | Janssen Biopharma, Inc. | Macrocyclic flu endonuclease inhibitors |
| WO2021129602A1 (zh) * | 2019-12-23 | 2021-07-01 | 石家庄迪斯凯威医药科技有限公司 | 取代的多环化合物及其药物组合物和用途 |
| WO2022105669A1 (zh) * | 2020-11-17 | 2022-05-27 | 南京明德新药研发有限公司 | 含Se大环类化合物 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8501542D0 (en) | 1985-01-22 | 1985-02-20 | Erba Farmitalia | 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives |
| AUPM354694A0 (en) | 1994-01-27 | 1994-02-17 | Biota Scientific Management Pty Ltd | Chemical compounds |
| DK2266958T1 (da) | 2001-08-10 | 2016-04-04 | Shionogi & Co | Antiviralt middel |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| EP1725554A1 (en) | 2004-03-09 | 2006-11-29 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Hiv integrase inhibitors |
| FR2901795A1 (fr) | 2006-05-30 | 2007-12-07 | Fourtillan Snc | Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique |
| BRPI0921701B8 (pt) | 2008-10-31 | 2022-06-07 | Shionogi & Co | Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| EP2412708A4 (en) | 2009-03-26 | 2014-07-23 | Shionogi & Co | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE |
| EP2444400B1 (en) | 2009-06-15 | 2018-03-28 | Shionogi&Co., Ltd. | Substituted polycyclic carbamoylpyridone derivative |
| MX2012007273A (es) | 2009-12-23 | 2012-12-17 | Elan Pharm Inc | Pteridinonas como inhibidores de la quinasa tipo polo. |
| TW201201813A (en) | 2010-03-31 | 2012-01-16 | Arqule Inc | Substituted benzo-pyrido-triazolo-diazepine compounds |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| RU2608519C2 (ru) | 2010-09-24 | 2017-01-19 | Шионоги энд Ко. Лтд. | Пролекарственная форма замещенного полициклического производного карбамоилпиридона |
| US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
| US9200009B2 (en) | 2011-10-12 | 2015-12-01 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase inhibitory activity |
| KR101520302B1 (ko) | 2012-09-20 | 2015-05-15 | (주)셀트리온 | 돌라스타틴 10 유도체, 그의 제조방법 및 그를 포함하는 항암제 조성물 |
| CA2894642A1 (en) | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| SG11201600977XA (en) | 2013-08-21 | 2016-03-30 | Alios Biopharma Inc | Antiviral compounds |
| CN105530946A (zh) | 2013-09-11 | 2016-04-27 | 南加利福尼亚大学 | 具有高度表达的fas配体的干细胞组合物 |
| KR102468319B1 (ko) * | 2013-09-12 | 2022-11-16 | 얀센 바이오파마, 인코퍼레이트. | 아자-피리돈 화합물 및 이의 용도 |
| CA2922943A1 (en) | 2013-09-12 | 2015-03-19 | Alios Biopharma, Inc. | Pyridazinone compounds and uses thereof |
| CA2953862A1 (en) | 2014-07-07 | 2016-01-14 | F. Hoffmann-La Roche Ag | Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases |
| US10208045B2 (en) | 2015-03-11 | 2019-02-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| WO2017153919A1 (en) | 2016-03-08 | 2017-09-14 | Novartis Ag | Tricyclic compounds useful to treat orthomyxovirus infections |
| WO2017156407A1 (en) | 2016-03-10 | 2017-09-14 | Alios Biopharma, Inc. | Method of preparing aza-pyridone compounds |
| EP3858835A1 (en) | 2016-07-01 | 2021-08-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| AR109315A1 (es) | 2016-08-10 | 2018-11-21 | Shionogi & Co | Composiciones farmacéuticas que contienen derivados de piridona policíclica sustituida y profármaco de las mismas |
| JOP20170169A1 (ar) * | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| JP2019059697A (ja) * | 2017-09-28 | 2019-04-18 | 塩野義製薬株式会社 | 置換された多環性ピリダジン誘導体およびそのプロドラッグ |
| CN110041327B (zh) | 2018-01-17 | 2022-01-21 | 江西彩石医药科技有限公司 | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |
| CN111848614B (zh) | 2018-01-17 | 2021-11-23 | 江西彩石医药科技有限公司 | 吡啶酮衍生物及抗流感病毒药物组合物 |
| CA3088000A1 (en) | 2018-02-28 | 2019-09-06 | Japan Tobacco Inc. | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof |
| PE20210550A1 (es) | 2018-02-28 | 2021-03-17 | Japan Tobacco Inc | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico |
| SG11202007718SA (en) | 2018-02-28 | 2020-09-29 | Novartis Ag | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza |
| RU2020131012A (ru) | 2018-02-28 | 2022-03-28 | Ф. Хоффманн-Ля Рош Аг | 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени |
-
2016
- 2016-08-29 JO JOP/2017/0169A patent/JOP20170169A1/ar unknown
-
2017
- 2017-08-25 PL PL17771587T patent/PL3504214T3/pl unknown
- 2017-08-25 EP EP17771587.7A patent/EP3504214B1/en active Active
- 2017-08-25 US US15/686,652 patent/US10160764B2/en active Active
- 2017-08-25 PT PT202103297T patent/PT3848372T/pt unknown
- 2017-08-25 PL PL20210329.7T patent/PL3848372T3/pl unknown
- 2017-08-25 WO PCT/IB2017/055137 patent/WO2018042303A1/en unknown
- 2017-08-25 PT PT177715877T patent/PT3504214T/pt unknown
- 2017-08-25 SI SI201731493T patent/SI3848372T1/sl unknown
- 2017-08-25 SI SI201730650T patent/SI3504214T1/sl unknown
- 2017-08-25 CN CN202110956692.7A patent/CN113683614A/zh active Pending
- 2017-08-25 US US16/328,616 patent/US11098051B2/en active Active
- 2017-08-25 EP EP20210329.7A patent/EP3848372B1/en active Active
- 2017-08-25 EP EP23217305.4A patent/EP4356969A3/en active Pending
- 2017-08-25 CA CA3035302A patent/CA3035302A1/en active Pending
- 2017-08-25 JP JP2019511749A patent/JP7221861B2/ja active Active
- 2017-08-25 MX MX2019002438A patent/MX2019002438A/es unknown
- 2017-08-25 CN CN201780065653.XA patent/CN109863151B/zh active Active
- 2017-08-25 ES ES17771587T patent/ES2859510T3/es active Active
- 2017-08-28 UY UY0001037378A patent/UY37378A/es unknown
- 2017-08-28 TW TW112101158A patent/TW202342482A/zh unknown
- 2017-08-28 TW TW106129086A patent/TWI803467B/zh active
- 2017-08-29 AR ARP170102385A patent/AR109438A1/es unknown
-
2021
- 2021-07-13 US US17/374,237 patent/US11912715B2/en active Active
-
2022
- 2022-11-22 JP JP2022186394A patent/JP2023027102A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SI3504214T1 (sl) | 2021-04-30 |
| EP3504214A1 (en) | 2019-07-03 |
| US20180057501A1 (en) | 2018-03-01 |
| EP3848372B1 (en) | 2023-12-20 |
| TWI803467B (zh) | 2023-06-01 |
| SI3848372T1 (sl) | 2024-04-30 |
| JOP20170169A1 (ar) | 2019-01-30 |
| UY37378A (es) | 2018-03-23 |
| PT3504214T (pt) | 2021-03-04 |
| CA3035302A1 (en) | 2018-03-08 |
| US20200123167A1 (en) | 2020-04-23 |
| CN109863151A (zh) | 2019-06-07 |
| JP2019532033A (ja) | 2019-11-07 |
| AR109438A1 (es) | 2018-11-28 |
| US20220041610A1 (en) | 2022-02-10 |
| MX2019002438A (es) | 2019-07-08 |
| US11912715B2 (en) | 2024-02-27 |
| ES2859510T3 (es) | 2021-10-04 |
| TW202342482A (zh) | 2023-11-01 |
| US10160764B2 (en) | 2018-12-25 |
| PT3848372T (pt) | 2024-03-22 |
| CN109863151B (zh) | 2021-09-10 |
| EP3848372A1 (en) | 2021-07-14 |
| JP2023027102A (ja) | 2023-03-01 |
| PL3848372T3 (pl) | 2024-04-22 |
| TW201811800A (zh) | 2018-04-01 |
| EP4356969A3 (en) | 2024-05-22 |
| CN113683614A (zh) | 2021-11-23 |
| EP4356969A2 (en) | 2024-04-24 |
| US11098051B2 (en) | 2021-08-24 |
| EP3504214B1 (en) | 2020-12-02 |
| WO2018042303A1 (en) | 2018-03-08 |
| JP7221861B2 (ja) | 2023-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3504214T3 (pl) | Skondensowane trójpierścieniowe związki pirydazynonowe przydatne w leczeniu infekcji ortomyksowirusami | |
| IL263972A (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| HK1244276A1 (zh) | 用於治療hiv的稠合嘧啶化合物 | |
| PL3178817T3 (pl) | Postać amorficzna związku tetracyklicznego | |
| EP3303341A4 (en) | Fused tricyclic heterocyclic compounds useful for treating hiv infection | |
| SG11201609652RA (en) | Treatment of polybacterials infections | |
| IL254424A0 (en) | Disubstituted heterocyclic tricyclic compounds | |
| HK1251465A1 (zh) | 包含三環雜環化合物的組合物 | |
| PT3535257T (pt) | Processo para a purificação de pirazolpiridazinas | |
| SG11201702274RA (en) | Process for purification of organic composition | |
| IL249907A0 (en) | Tricyclic substances containing a triazole ring | |
| IL260094A (en) | Treatment of hand eczema | |
| GB201409161D0 (en) | Routing scheme switching | |
| IL248838B (en) | Compressed heteroaromatic spirocyclic compounds for the treatment of bacterial infections | |
| GB201404848D0 (en) | Pathogenic infections | |
| ZA201801775B (en) | Soap bar having separate concentrated regions of specifically selected components | |
| PL3494122T3 (pl) | Podstawione rybonukleozydy heteropentadienopirolopirymidynowe do użytku terapeutycznego | |
| ZA201700710B (en) | Pathogenic control of apoptosis | |
| PL3131890T3 (pl) | Związki do leczenia zakażeń wirusowych | |
| GB201510870D0 (en) | Treatment of infarction | |
| ZA201902183B (en) | Purification process of fviii | |
| ZA201804025B (en) | Inactivation of viruses by delipidation | |
| GB201619704D0 (en) | Treatment of pathogenic infections | |
| GB201512635D0 (en) | Uses of therapeutic compounds | |
| PL3137475T3 (pl) | Oczyszczanie epidaunorubicyny |